aspirin has been researched along with Colorectal Neoplasms, Hereditary Nonpolyposis in 45 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Colorectal Neoplasms, Hereditary Nonpolyposis: A group of autosomal-dominant inherited diseases in which COLON CANCER arises in discrete adenomas. Unlike FAMILIAL POLYPOSIS COLI with hundreds of polyps, hereditary nonpolyposis colorectal neoplasms occur much later, in the fourth and fifth decades. HNPCC has been associated with germline mutations in mismatch repair (MMR) genes. It has been subdivided into Lynch syndrome I or site-specific colonic cancer, and LYNCH SYNDROME II which includes extracolonic cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Several epidemiological studies have shown that regular use of low dose aspirin is associated with a 20 to 30% reduction in the risk of sporadic colonic adenomas and colorectal cancer regardless of family risk." | 9.34 | Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial. ( Ait-Omar, A; Benallaoua, M; Benamouzig, R; Boubaya, M; Deutsch, D; Helfen, S; Levy, V; Mary, F; Soualy, A, 2020) |
| "Obesity is associated with substantially increased CRC risk in patients with LS, but this risk is abrogated in those taking aspirin." | 9.20 | Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. ( Bertario, L; Bisgaard, ML; Bishop, DT; Burn, J; Dunlop, MG; Eccles, D; Evans, DG; Ho, JW; Hodgson, SV; Lindblom, A; Lubinski, J; Macrae, F; Maher, ER; Mathers, JC; Mecklin, JP; Moeslein, G; Morrison, PJ; Movahedi, M; Murday, V; Olschwang, S; Ramesar, RS; Scott, RJ; Side, L; Thomas, HJ; Vasen, HF, 2015) |
| " Use of aspirin has been shown to be associated with a reduced risk of colorectal cancer for the general population as well as for MMR gene mutation carriers." | 7.81 | Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. ( Ahnen, DJ; Ait Ouakrim, D; Baron, JA; Buchanan, DD; Casey, G; Chau, R; Clendenning, M; Dashti, SG; Gallinger, S; Giles, GG; Haile, RW; Hopper, JL; Jenkins, MA; Le Marchand, L; Leggett, B; Lindor, NM; Macrae, FA; Newcomb, PA; Potter, JD; Rosty, C; Thibodeau, SN; Win, AK; Winship, IM; Young, JP, 2015) |
| " Aspirin and sulindac have been shown to be effective in selecting for cells with reduced microsatellite instability (MSI) that is inherent in mismatch repair (MMR)-deficient hereditary nonpolyposis colorectal cancer (HNPCC) cells." | 7.74 | Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. ( Burkholder, S; Fishel, R; Kopelovich, L; McIlhatton, MA; Rigas, B; Ruschoff, J; Tyler, J, 2007) |
| "Regular bowel screening and aspirin reduce colorectal cancer among patients with LS but extracolonic cancers are difficult to detect and manage." | 5.51 | Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up. ( Bertario, L; Bishop, DT; Borthwick, GM; Burn, J; Elliott, F; Evans, DG; Gerdes, AM; Ho, JWC; Lindblom, A; Macrae, F; Mathers, JC; McRonald, FE; Mecklin, JP; Morrison, PJ; Möslein, G; Pylvänäinen, K; Ramesar, RS; Rashbass, J; Reed, L; Seppälä, TT; Sheth, HJ; Thomas, HJW, 2022) |
| " Several epidemiological studies have shown that regular use of low dose aspirin is associated with a 20 to 30% reduction in the risk of sporadic colonic adenomas and colorectal cancer regardless of family risk." | 5.34 | Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial. ( Ait-Omar, A; Benallaoua, M; Benamouzig, R; Boubaya, M; Deutsch, D; Helfen, S; Levy, V; Mary, F; Soualy, A, 2020) |
| "Obesity is associated with substantially increased CRC risk in patients with LS, but this risk is abrogated in those taking aspirin." | 5.20 | Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. ( Bertario, L; Bisgaard, ML; Bishop, DT; Burn, J; Dunlop, MG; Eccles, D; Evans, DG; Ho, JW; Hodgson, SV; Lindblom, A; Lubinski, J; Macrae, F; Maher, ER; Mathers, JC; Mecklin, JP; Moeslein, G; Morrison, PJ; Movahedi, M; Murday, V; Olschwang, S; Ramesar, RS; Scott, RJ; Side, L; Thomas, HJ; Vasen, HF, 2015) |
| "In a randomized, placebo-controlled trial, we used a two-by-two design to investigate the effects of aspirin, at a dose of 600 mg per day, and resistant starch (Novelose), at a dose of 30 g per day, in reducing the risk of adenoma and carcinoma among persons with the Lynch syndrome." | 5.13 | Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. ( Barker, G; Bertario, L; Bisgaard, ML; Bishop, DT; Burn, J; Dunlop, M; Eccles, D; Elliott, F; Evans, DG; Fodde, R; Ho, JW; Jarvinen, HJ; Jass, JR; Lindblom, A; Lubinski, J; Lynch, HT; Macrae, F; Maher, ER; Mathers, JC; Mecklin, JP; Morrison, PJ; Möslein, G; Olschwang, S; Ramesar, R; Scott, RJ; Side, L; Thomas, HJ; Vasen, HF, 2008) |
| "The strongest evidence is for non-steroidal anti-inflammatory drugs slowing polyp progression, notably Sulindac and aspirin in patients with familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer, respectively." | 4.95 | Chemoprevention of colorectal neoplasia. ( Eglinton, T; Eteuati, J; Frizelle, F; Hollington, P; Keenan, J; Wakeman, C, 2017) |
| " Use of aspirin has been shown to be associated with a reduced risk of colorectal cancer for the general population as well as for MMR gene mutation carriers." | 3.81 | Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. ( Ahnen, DJ; Ait Ouakrim, D; Baron, JA; Buchanan, DD; Casey, G; Chau, R; Clendenning, M; Dashti, SG; Gallinger, S; Giles, GG; Haile, RW; Hopper, JL; Jenkins, MA; Le Marchand, L; Leggett, B; Lindor, NM; Macrae, FA; Newcomb, PA; Potter, JD; Rosty, C; Thibodeau, SN; Win, AK; Winship, IM; Young, JP, 2015) |
| " Previous cellular studies showed that aspirin (acetylsalicylic acid: ASA) and nitric oxide-donating ASA (NO-ASA) suppressed microsatellite instability (MSI) in mismatch repair (MMR)-deficient cells linked to the common cancer predisposition syndrome hereditary nonpolyposis colorectal cancer or Lynch syndrome (LS/HNPCC), at doses 300- to 3,000-fold less than ASA." | 3.77 | Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model. ( Bocker-Edmonston, T; Edelmann, W; Fishel, R; Kerepesi, LA; Kopelovich, L; Kucherlapati, MH; Kucherlapati, R; McIlhatton, MA; Tyler, J, 2011) |
| " Aspirin and sulindac have been shown to be effective in selecting for cells with reduced microsatellite instability (MSI) that is inherent in mismatch repair (MMR)-deficient hereditary nonpolyposis colorectal cancer (HNPCC) cells." | 3.74 | Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. ( Burkholder, S; Fishel, R; Kopelovich, L; McIlhatton, MA; Rigas, B; Ruschoff, J; Tyler, J, 2007) |
| "Non-colorectal Lynch syndrome cancers were reported in 36 participants who received aspirin and 36 participants who received placebo." | 2.94 | Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. ( Bertario, L; Bishop, DT; Borthwick, GM; Burn, J; Elliott, F; Evans, DG; Gerdes, AM; Ho, JWC; Lindblom, A; Macrae, F; Mathers, JC; McRonald, FE; Mecklin, JP; Morrison, PJ; Möslein, G; Pylvänäinen, K; Ramesar, R; Rashbass, J; Reed, L; Seppälä, T; Sheth, H; Thomas, HJW, 2020) |
| "The CAPP2 study recruited 861 Lynch syndrome participants randomly assigned to 600 mg of aspirin versus placebo." | 2.82 | Aspirin Colorectal Cancer Prevention in Lynch Syndrome: Recommendations in the Era of Precision Medicine. ( Bertario, L; Bonanni, B; D'Arpino, A; Grattagliano, I; Oliani, C; Patrignani, P; Roviello, F; Sciallero, S; Serrano, D; Stigliano, V; Testa, S; Turchetti, D, 2022) |
| "Aspirin treatment resulted in a non-significant reduction in polyp number and a significant reduction in polyp size among patients treated with aspirin for more than 1 year." | 2.78 | Chemoprevention in Lynch syndrome. ( Bishop, DT; Burn, J; Mathers, JC, 2013) |
| "Lynch syndrome is the most common genetic predisposition for hereditary cancer but remains underdiagnosed." | 2.72 | European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. ( Burn, J; Crosbie, EJ; Dominguez-Valentin, M; Duijnhoven, FJBV; Evans, DG; Jimenez-Rodriguez, R; Kloor, M; Knebel Doeberitz, MV; Latchford, A; Möslein, G; Møller, P; Negoi, I; Quirke, P; Ryan, N; Sampaio Soares, A; Sampson, JR; Sánchez-Guillén, L; Seppälä, TT, 2021) |
| "Side effects, such as arrhythmia, angina pectoris, and nervous headache, were observed in the celecoxib 400 mg/d group." | 2.72 | [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis]. ( Geng, HG; Li, SR; Sheng, JQ; Su, H; Yan, W; Yang, XY; Yu, DL; Zhang, YH, 2006) |
| "This syndrome results in early onset colorectal cancer, leukemia and lymphoma, brain tumors and other malignancies." | 2.58 | Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD). ( Brüggemann, RJ; Burn, J; Hoogerbrugge, N; Jongmans, MCJ; Kratz, C; Leenders, EKSM; Loeffen, J; Westdorp, H, 2018) |
| "Lynch syndrome is an autosomal-dominant hereditary cancer syndrome." | 2.55 | Approach to Lynch Syndrome for the Gastroenterologist. ( Bui, QM; Ho, W; Lin, D, 2017) |
| "In CAPP2, 1009 Lynch syndrome gene carriers were recruited from 43 international centres." | 2.49 | Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). ( Bishop, DT; Burn, J; Mathers, J, 2013) |
| "GPs report limited awareness of Lynch Syndrome and the preventive effects of aspirin among carriers." | 1.46 | General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey. ( Brown, K; Burn, J; Cuzick, J; Foy, R; Kobayashi, LC; McGowan, J; Side, L; Smith, SG, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.44) | 18.2507 |
| 2000's | 8 (17.78) | 29.6817 |
| 2010's | 25 (55.56) | 24.3611 |
| 2020's | 10 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Serrano, D | 1 |
| Patrignani, P | 1 |
| Stigliano, V | 1 |
| Turchetti, D | 1 |
| Sciallero, S | 1 |
| Roviello, F | 1 |
| D'Arpino, A | 1 |
| Grattagliano, I | 1 |
| Testa, S | 1 |
| Oliani, C | 1 |
| Bertario, L | 6 |
| Bonanni, B | 1 |
| Mathers, JC | 7 |
| Elliott, F | 4 |
| Macrae, F | 7 |
| Mecklin, JP | 5 |
| Möslein, G | 4 |
| McRonald, FE | 2 |
| Evans, DG | 6 |
| Gerdes, AM | 3 |
| Ho, JWC | 2 |
| Lindblom, A | 5 |
| Morrison, PJ | 5 |
| Rashbass, J | 2 |
| Ramesar, RS | 2 |
| Seppälä, TT | 2 |
| Thomas, HJW | 2 |
| Sheth, HJ | 1 |
| Pylvänäinen, K | 3 |
| Reed, L | 2 |
| Borthwick, GM | 3 |
| Bishop, DT | 8 |
| Burn, J | 11 |
| Lloyd, KE | 1 |
| Hall, LH | 1 |
| Ziegler, L | 1 |
| Foy, R | 2 |
| MacKenzie, M | 1 |
| Taylor, DG | 1 |
| Smith, SG | 2 |
| Monahan, KJ | 1 |
| Swinyard, O | 1 |
| Latchford, A | 2 |
| Meiser, B | 2 |
| Kaur, R | 2 |
| Kirk, J | 2 |
| Morrow, A | 1 |
| Peate, M | 2 |
| Wong, WKT | 1 |
| McPike, E | 1 |
| Cops, E | 1 |
| Dowson, C | 1 |
| Austin, R | 1 |
| Fine, M | 1 |
| Thrupp, L | 1 |
| Ward, R | 1 |
| Hiller, JE | 1 |
| Trainer, AH | 2 |
| Mitchell, G | 2 |
| Yurgelun, MB | 1 |
| Chan, AT | 3 |
| Sheth, H | 1 |
| Ramesar, R | 3 |
| Seppälä, T | 1 |
| Soualy, A | 1 |
| Deutsch, D | 1 |
| Benallaoua, M | 1 |
| Ait-Omar, A | 1 |
| Mary, F | 1 |
| Helfen, S | 1 |
| Boubaya, M | 1 |
| Levy, V | 1 |
| Benamouzig, R | 1 |
| Lynch, PM | 2 |
| Negoi, I | 1 |
| Sampaio Soares, A | 1 |
| Jimenez-Rodriguez, R | 1 |
| Sánchez-Guillén, L | 1 |
| Ryan, N | 1 |
| Crosbie, EJ | 1 |
| Dominguez-Valentin, M | 1 |
| Kloor, M | 1 |
| Knebel Doeberitz, MV | 1 |
| Duijnhoven, FJBV | 1 |
| Quirke, P | 1 |
| Sampson, JR | 1 |
| Møller, P | 1 |
| McGowan, J | 1 |
| Kobayashi, LC | 1 |
| Brown, K | 1 |
| Side, L | 4 |
| Cuzick, J | 1 |
| Moayyedi, P | 2 |
| Leenders, EKSM | 1 |
| Westdorp, H | 1 |
| Brüggemann, RJ | 1 |
| Loeffen, J | 1 |
| Kratz, C | 1 |
| Hoogerbrugge, N | 1 |
| Jongmans, MCJ | 1 |
| Ait Ouakrim, D | 2 |
| Dashti, SG | 2 |
| Chau, R | 1 |
| Buchanan, DD | 1 |
| Clendenning, M | 1 |
| Rosty, C | 1 |
| Winship, IM | 1 |
| Young, JP | 1 |
| Giles, GG | 1 |
| Leggett, B | 1 |
| Macrae, FA | 1 |
| Ahnen, DJ | 2 |
| Casey, G | 1 |
| Gallinger, S | 1 |
| Haile, RW | 1 |
| Le Marchand, L | 1 |
| Thibodeau, SN | 1 |
| Lindor, NM | 1 |
| Newcomb, PA | 1 |
| Potter, JD | 1 |
| Baron, JA | 1 |
| Hopper, JL | 1 |
| Jenkins, MA | 1 |
| Win, AK | 2 |
| Movahedi, M | 2 |
| Moeslein, G | 2 |
| Olschwang, S | 3 |
| Eccles, D | 3 |
| Maher, ER | 3 |
| Bisgaard, ML | 3 |
| Dunlop, MG | 3 |
| Ho, JW | 3 |
| Hodgson, SV | 2 |
| Lubinski, J | 3 |
| Murday, V | 2 |
| Scott, RJ | 3 |
| Thomas, HJ | 3 |
| Vasen, HF | 3 |
| Wakeman, C | 1 |
| Keenan, J | 1 |
| Eteuati, J | 1 |
| Hollington, P | 1 |
| Eglinton, T | 1 |
| Frizelle, F | 1 |
| Tuccori, M | 1 |
| Filion, KB | 1 |
| Azoulay, L | 1 |
| Walcott, FL | 1 |
| Patel, J | 1 |
| Lubet, R | 1 |
| Rodriguez, L | 1 |
| Calzone, KA | 1 |
| Ricciardiello, L | 1 |
| Chen, Y | 1 |
| Wong, T | 1 |
| Ward, RL | 1 |
| Goodwin, A | 1 |
| Hiller, J | 1 |
| Bui, QM | 1 |
| Lin, D | 1 |
| Ho, W | 1 |
| Jarvinen, HJ | 1 |
| Dunlop, M | 1 |
| Barker, G | 2 |
| Jass, JR | 1 |
| Fodde, R | 2 |
| Lynch, HT | 2 |
| Yang, F | 1 |
| Jin, C | 1 |
| Fu, D | 1 |
| Topping, DL | 1 |
| Bird, AR | 1 |
| Young, GP | 1 |
| McIlhatton, MA | 2 |
| Tyler, J | 2 |
| Kerepesi, LA | 1 |
| Bocker-Edmonston, T | 1 |
| Kucherlapati, MH | 1 |
| Edelmann, W | 1 |
| Kucherlapati, R | 1 |
| Kopelovich, L | 2 |
| Fishel, R | 3 |
| Lippman, SM | 1 |
| Crawford, G | 1 |
| Wijnen, JT | 1 |
| Maxwell, PH | 1 |
| McNeil, C | 1 |
| Jankowski, J | 1 |
| Barr, H | 1 |
| Cleland, JG | 1 |
| Ferrández, A | 1 |
| Piazuelo, E | 1 |
| Castells, A | 1 |
| Mathers, J | 2 |
| Coxhead, JM | 1 |
| Williams, EA | 1 |
| Sheng, JQ | 1 |
| Li, SR | 1 |
| Yang, XY | 1 |
| Zhang, YH | 1 |
| Su, H | 1 |
| Yu, DL | 1 |
| Yan, W | 1 |
| Geng, HG | 1 |
| Burkholder, S | 1 |
| Ruschoff, J | 2 |
| Rigas, B | 1 |
| Wallinger, S | 1 |
| Dietmaier, W | 1 |
| Bocker, T | 1 |
| Brockhoff, G | 1 |
| Hofstädter, F | 1 |
| Seidensticker, F | 1 |
| Schmiegel, WH | 1 |
| Lamberti, C | 1 |
| Jungck, M | 1 |
| Caspari, R | 1 |
| Schmidt-Wolf, I | 1 |
| Sauerbruch, T | 1 |
| Sansom, OJ | 1 |
| Stark, LA | 1 |
| Clarke, AR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Inherited Cancer Early Diagnosis (ICED) Study Liquid Biopsy Screening for Early Diagnosis of Cancers in Patients With Cancer-predisposition Syndromes[NCT06163365] | 100 participants (Anticipated) | Observational [Patient Registry] | 2022-07-26 | Recruiting | |||
| Assessment of the Effect of a Daily Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome[NCT02813824] | Phase 3 | 852 participants (Anticipated) | Interventional | 2017-11-14 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for aspirin and Colorectal Neoplasms, Hereditary Nonpolyposis
| Article | Year |
|---|---|
Aspirin Colorectal Cancer Prevention in Lynch Syndrome: Recommendations in the Era of Precision Medicine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms, Hereditary Nonpolyposis; Het | 2022 |
Biology of Precancers and Opportunities for Cancer Interception: Lesson from Colorectal Cancer Susceptibility Syndromes.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biology; Colorectal Ne | 2023 |
European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Colonoscopy; Colorectal Neoplasms | 2021 |
Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD).
Topics: Aspirin; Brain Neoplasms; Child; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis | 2018 |
Chemoprevention of colorectal neoplasia.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, No | 2017 |
Hereditary cancer syndromes as model systems for chemopreventive agent development.
Topics: Adaptor Proteins, Signal Transducing; Adenomatous Polyposis Coli; Adenosine Triphosphatases; Animals | 2016 |
Chemoprevention of hereditary colon cancers: time for new strategies.
Topics: Adenomatous Polyposis Coli; Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy P | 2016 |
Approach to Lynch Syndrome for the Gastroenterologist.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Colectomy; Colonoscopy; Colore | 2017 |
Aspirin and the prevention of colorectal cancer.
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Ne | 2012 |
Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aspirin; Child; Colorectal Neoplasms, Hereditary Nonp | 2013 |
DNA mismatch repair status may influence anti-neoplastic effects of butyrate.
Topics: Anticarcinogenic Agents; Aspirin; Base Pair Mismatch; Butyrates; Cell Line, Tumor; Colorectal Neopla | 2005 |
[Practice-relevant intestinal diseases: prevention of colon carcinoma].
Topics: Adenomatous Polyposis Coli; Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyp | 1998 |
9 trials available for aspirin and Colorectal Neoplasms, Hereditary Nonpolyposis
| Article | Year |
|---|---|
Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up.
Topics: Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Follow-Up Studies; Hum | 2022 |
GPs' willingness to prescribe aspirin for cancer preventive therapy in Lynch syndrome: a factorial randomised trial investigating factors influencing decisions.
Topics: Aspirin; Colorectal Neoplasms, Hereditary Nonpolyposis; England; Humans; Risk Assessment; Surveys an | 2023 |
Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms, Hereditary Nonpolyposis; Dou | 2020 |
Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial.
Topics: Adenoma; Adult; Aspirin; Chemoprevention; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Non | 2020 |
Chemoprevention in Lynch syndrome.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms, Hereditary Nonpo | 2013 |
Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study.
Topics: Adaptor Proteins, Signal Transducing; Adiposity; Adult; Anti-Inflammatory Agents, Non-Steroidal; Asp | 2015 |
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.
Topics: Adenoma; Adult; Aged; Aspirin; Carcinoma; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Non | 2008 |
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Colorectal Neoplasms, He | 2011 |
[Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Angina Pectoris; Anti-Inflammatory Agents, Non- | 2006 |
24 other studies available for aspirin and Colorectal Neoplasms, Hereditary Nonpolyposis
| Article | Year |
|---|---|
Evaluation of implementation of risk management guidelines for carriers of pathogenic variants in mismatch repair genes: a nationwide audit of familial cancer clinics.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Colonoscopy; Colorectal Neoplasms; Colorectal Neoplasms, He | 2020 |
Aspirin for Lynch syndrome: a legacy of prevention.
Topics: Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Double-Blind Method; F | 2020 |
The CAPP II trial of aspirin in Lynch syndrome/HNPCC: is it time for everyone to be treated?
Topics: Age Factors; Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Drug Admi | 2021 |
General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey.
Topics: Aspirin; Attitude of Health Personnel; Colorectal Neoplasms, Hereditary Nonpolyposis; Female; Genera | 2017 |
Signature Celebration of Gastroenterology, Colorectal Cancer.
Topics: Adenomatous Polyps; Anticarcinogenic Agents; Aspirin; Biomedical Research; Colonic Polyps; Colorecta | 2018 |
Aspirin may help colon cancer patients live longer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Colorectal Neoplasms, Hereditar | 2013 |
Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Adult; Aged; Anti-Inflammatory Agen | 2015 |
Lynch Syndrome: AGA Patient Guideline Summary.
Topics: Aspirin; Colonoscopy; Colorectal Neoplasms, Hereditary Nonpolyposis; Decision Support Techniques; Ga | 2015 |
RE: Aspirin, Ibuprofen, and the Risk for Colorectal Cancer in Lynch Syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neoplasms; Col | 2016 |
Response.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neoplasms; Col | 2016 |
Exploring clinicians' attitudes about using aspirin for risk reduction in people with Lynch Syndrome with no personal diagnosis of colorectal cancer.
Topics: Aspirin; Australia; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Cross-Secti | 2017 |
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Confounding F | 2009 |
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Humans; Starc | 2009 |
Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Base Pair Mismatch; Colorectal Neoplasms, | 2011 |
Aspirin and colorectal cancer prevention in Lynch syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms, Hereditary Nonpolyposis; Het | 2011 |
Tumor strengths and frailties: Aspiring to prevent colon cancer.
Topics: Aspirin; Cell Transformation, Neoplastic; Colonic Neoplasms; Colorectal Neoplasms, Hereditary Nonpol | 2012 |
New data on aspirin and colorectal cancer brings calls for new guidelines, more research.
Topics: Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; | 2012 |
Does aspirin really reduce the risk of colon cancer?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms, Hereditary Nonpolyposis; Het | 2012 |
Does aspirin really reduce the risk of colon cancer?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms, Hereditary Nonpolyposis; Het | 2012 |
Lynch syndrome: history, causes, diagnosis, treatment and prevention (CAPP2 trial).
Topics: Anticarcinogenic Agents; Aspirin; Colorectal Neoplasms, Hereditary Nonpolyposis; DNA Mismatch Repair | 2012 |
Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells.
Topics: Animals; Aspirin; Base Pair Mismatch; Cell Line, Tumor; Colon; Colorectal Neoplasms, Hereditary Nonp | 2007 |
Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection.
Topics: Adaptor Proteins, Signal Transducing; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; C | 1998 |
[Therapy and after-care of familial adenomatous polyposis and hereditary colorectal carcinoma without polyposis].
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aftercare; Anti-Inflammatory Agents, Non-Steroidal; A | 2000 |
Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Base Pair Mismatch; Colorectal Neoplasms, | 2001 |